EN DE
Watch Fakeeh Care for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Fakeeh Care (4017) fair value: what the stock is really worth

As of Oct 29, 2026: fair value (intrinsic value) of Fakeeh Care stock SAR 25.73, price SAR 30.32, upside -15.1%, quality 38 out of 100. Rating: overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare SA · ISIN SA562GSHUOH7

FC Fakeeh Care logo Some data Oct 28, 2026

Fakeeh Care

4017 · SR
Expensive, weak quality

Our calculation puts a fair price 15% below what the stock costs today.

Low debt
Expensive Growth (revenue 5y +12.5 %/yr in SAR)
Thin margins · 7.5% net margin (TTM)
1.1% dividend yield · Watch coverage
Some data
Profit last quarter 31% below a year ago.
Fair value 25.73 SAR · Overvalued (−15.1%)
Quality 38/100
Negative free cash flow
Trails peers (3/13)
Narrow moat 41/100
⚠ Small free float
Watch Fakeeh Care for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

70.44 SAR 28.70 SAR Fair Value 25.73 SAR Jun 2024 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 28, 2026.

How to read this chart

29‑month range 28.70 SAR – 70.44 SAR · fair‑value band 18.50 SAR – 32.96 SAR · the 30.32 SAR price screens above the 25.73 SAR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 28, 2026.

Follow Fakeeh Care in your weekly email

Every Wednesday you see whether Fakeeh Care is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Dr. Soliman Abdel Kader Fakeeh Hospital Company, together with its subsidiaries, establishes, operates, and manages hospitals, clinics, medical, educational, and training centers in the Kingdom of Saudi Arabia.

Show moreShow less

The company operates through Medical Services; Education; and Trading, Retail & Others segments.

It provides various services, such as assisted reproductive therapy, audiology, bariatric surgery, pediatric, breast feeding, cardiac surgery, cardiology, chest and respiratory diseases, chiropractic medicine, dental and maxillofacial, dermatology, otorhinolaryngology, endocrinology, ophthalmology, family medicine, gastroenterology, general surgery, geriatric medicine, hematology, hyperbaric oxygen service, infectious diseases, internal medicine, interventional radiology, psychiatry, lasik surgery, nephrology, neuro surgery, neurology, nutrition, obstetrics and gynecology, oncology, orthopedics, pediatric orthopedic surgery, pediatric surgery, physical medicine and rehabilitation, plastic surgery, rheumatology, sleep disorders clinic, speech therapy, thoracic surgery, urology, and vascular surgery, as well as pain treatment and palliative care services.

The company also operates AIRS, anesthesia, burn, diagnostics service, emergency medicine, endoscopy, intensive care, NICU, renal dialysis, rhinoplasty, and institute of robotic surgery facilities; establishes and manages pharmacies; and provides analysis and radiology laboratory, healthcare, medical education, and home health care services.

In addition, it engages in the trading of pharmaceutical products, spectacles, and cosmetics; construction and contracting; wholesale and retail of medical equipment; and maintenance of IT equipment and software related services.

The company was incorporated in 1978 and is based in Jeddah, the Kingdom of Saudi Arabia.

Stock analysis

Fakeeh Care (4017) currently trades at 30.32 SAR, while our model-based Fair Value estimate is 25.73 SAR, 15.1% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 26.56 SAR per share, and 2 of the 16 models we run sit above the 30.32 SAR price.

Bear case: the Dividend Discount group reads lowest at 3.55 SAR, and 14 of the 16 models stay below the price. Data coverage for this calculation is medium.

Scenario range: 18.50 SAR (bear) to 32.96 SAR (bull), the price of 30.32 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Fakeeh Care reported revenue of 3.1B SAR in FY2025 versus 2.0B SAR in FY2021, a compound +12.0%/yr. Reported net income was 290M SAR in FY2025, compounding −3.5%/yr from FY2021.

Key figures

Market cap 7.0B SAR (≈ $1.9B) Small · P/E ratio 30.0 · P/S ratio 2.25 · EPS (TTM) 1.01 SAR · Dividend yield 1.1% · Net margin 7.5% · Return on equity 5.5% · Return on assets (EBIT) 7.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 41 out of 100 (medium confidence).

What moves the price

The share trades about 28% below its 52-week high and 6% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at −15%, 4017 screens richer than that median.

Fair Value models

Bear 18.50 SAR Fair Value 25.73 SAR Bull 32.96 SAR
Price 30.32 SAR · Upside -15.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.5645 SAR per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income 10.86 SAR 11.48 SAR 12.87 SAR 76
EPV 9.00 SAR 10.08 SAR 10.98 SAR 74
ROIC Compounder 9.00 SAR 10.08 SAR 10.98 SAR 72
All 16 models by family
Earnings-Based
Graham-Dodd 8.58 SAR 44.22 SAR 61.13 SAR 64
Lynch FV 12.07 SAR 17.25 SAR 22.42 SAR 61
PEG = 1.0 12.07 SAR 17.25 SAR 22.42 SAR 57
EPV 9.00 SAR 10.08 SAR 10.98 SAR 74
Dividend Discount
Gordon GGM 2.20 SAR 3.80 SAR 5.06 SAR 68
DDM Multi-Stage 2.20 SAR 3.55 SAR 4.08 SAR 67
Multiples
P/E Multiple 20.82 SAR 27.76 SAR 34.70 SAR 63
P/S Multiple 16.09 SAR 21.45 SAR 26.81 SAR 58
P/B Multiple 38.51 SAR 51.35 SAR 64.19 SAR 55
EV/EBIT 13.04 SAR 18.46 SAR 23.87 SAR 65
EV/EBITDA 18.50 SAR 25.73 SAR 32.96 SAR 67
EV/Revenue 8.39 SAR 13.36 SAR 18.33 SAR 53
Asset-Based
NCAV (Graham) 5.71 SAR 7.65 SAR 11.41 SAR 54
Economic Profit
Residual Income 10.86 SAR 11.48 SAR 12.87 SAR 76
ROIC Compounder 9.00 SAR 10.08 SAR 10.98 SAR 72
Growth Earnings
Growth-Adj P/E 18.59 SAR 26.56 SAR 34.52 SAR 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 37
How much profit the company makes from its sales and capital
Quality Growth 36
Are margins and returns getting better?
Cashflow 36
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 34
Does it invest with discipline instead of growing at any price?
Low Volatility 88
How calm the share price moves, does not count
Momentum 23
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 9
Distance to the 52-week high, does not count
New shares 27
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+10.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.5%
Start year 2020 (pandemic)
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−12.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−14.0%
Dividend (yield on the price)1.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 10%

4017 screens overvalued: fair value 15% below the price. Compare with HCA Healthcare, Inc →

Compare Fakeeh Care with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 242 stocks

Beats the industry median on 3/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 38 · Bottom 25%
Fair Value upside −15.1% · Below median
Profitability
Return on equity (12 months) 5.5% · Below median
Return on assets 5.0% · Above median
Net margin (12 months) 7.5% · Above median
Operating margin (12 months) 8.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) −1.6% · Bottom 25%
Dividend yield (12 months) 1.1% · Below median
Balance sheet
Debt / equity 0.11× · Below median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 30.0× · Pricier than median
P/B 2.20× · Pricier than median
P/S (12 months) 2.25× · Pricier than median
EV/EBITDA 17.6× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)13 · sector 37
FUTURE (revenue growth)0 · sector 31
PAST (return on equity)22 · sector 33
HEALTH (low debt)95 · sector 90
DIVIDEND (yield)22 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Universal Health Services, Inc UHS $177.32 $447.22 +152% vs 4017
Fresenius Medical Care AG FME €40.57 €71.94 +77% vs 4017
HCA Healthcare, Inc HCA $449.96 $612.42 +36% vs 4017
Aier Eye Hospital Group 300015 ¥8.25 ¥10.86 +32% vs 4017
DaVita Inc DVA $181.69 $215.81 +19% vs 4017
Tenet Healthcare Corporation THC $262.05 $276.08 +5% vs 4017
Encompass Health Corporation EHC $122.09 $94.47 −23% vs 4017
Fresenius SE FRE €46.26 €34.56 −25% vs 4017
Dr. Sulaiman Al Habib Medical Services Group 4013 221.00 SAR 109.45 SAR −50% vs 4017
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹7,792 ₹2,908 −63% vs 4017

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Fakeeh Care · Fair Value
25.73 SAR −15%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Fakeeh Care Fair Value". https://www.fairvalue-calculator.com/stock/4017

Frequently asked questions

Is Fakeeh Care (4017) overvalued or undervalued?
As of Oct 28, 2026, our model estimates a fair value of 25.73 SAR versus a price of 30.32 SAR, about −15% upside (overvalued).
What is the fair value of 4017?
Our model-based fair value for Fakeeh Care is 25.73 SAR (as of Oct 28, 2026), built from audited fundamentals. The current price: 30.32 SAR.
What is the quality score of 4017?
Fakeeh Care has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Fakeeh Care (4017)?
Our model-based price target is the fair value of 25.73 SAR (as of Oct 28, 2026) from 16 valuation models. Cautious scenario 18.50 SAR, optimistic scenario 32.96 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Fakeeh Care stock forecast for 2026?
Our models put fair value at 25.73 SAR, about −15% upside versus a price of 30.32 SAR (overvalued). Cautious scenario 18.50 SAR, optimistic scenario 32.96 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Fakeeh Care (4017)?
Fakeeh Care reported trailing-twelve-month revenue of about 3.1B SAR (latest available figure, as of Oct 28, 2026).
Does Fakeeh Care pay a dividend?
Fakeeh Care currently shows a dividend yield of 1.09% relative to its recent price (as of Oct 28, 2026).
What is the intrinsic value of Fakeeh Care (4017)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Fakeeh Care it is 25.73 SAR per share (as of Oct 28, 2026), against a price of 30.32 SAR. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Fakeeh Care stock overvalued or undervalued in 2026?
As of Oct 28, 2026, 4017 trades above its calculated fair value: price 30.32 SAR, fair value 25.73 SAR, a gap of about −15% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4017?
No. The price is what the market pays today (30.32 SAR); the fair value is what the company's own numbers justify (25.73 SAR). For Fakeeh Care the two are 4.59 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Fakeeh Care worth?
The market values Fakeeh Care at about 7.0B SAR (market capitalisation, as of Oct 28, 2026). Per share that is 30.32 SAR; our models calculate a fair value of 25.73 SAR per share.
What do the bullish and bearish scenarios say about 4017?
Our models span a range for Fakeeh Care: cautious scenario 18.50 SAR, base 25.73 SAR, optimistic 32.96 SAR per share (as of Oct 28, 2026, price 30.32 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 4017?
Fakeeh Care trades at a price-to-earnings ratio of 30.0 (as of Oct 28, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 25.73 SAR is built from several models across several years. Other multiples: P/B 2.2, P/S 2.2, EV/EBITDA 17.6.
How solid is the balance sheet of Fakeeh Care (4017)?
Balance-sheet figures for Fakeeh Care (as of Oct 28, 2026): return on equity 5.5%, debt of 0.11 per unit of equity. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is 4017 from its 52-week high?
Fakeeh Care trades at 30.32 SAR, about 28% below its 52-week high of 42.22 SAR and 6% above the low of 28.70 SAR (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of 25.73 SAR is for.
Which stocks are comparable to Fakeeh Care?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Fakeeh Care stock attractive at the current price?
The data as of Oct 28, 2026: price 30.32 SAR, calculated fair value 25.73 SAR (−15%), Quality Score 38/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4017 calculated?
We run Fakeeh Care through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 25.73 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3 % above its aggregate fair value. Fakeeh Care itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Fakeeh Care (4017)?
The closing price on Oct 29, 2026 was 30.32 SAR. Our model-based fair value is 25.73 SAR, about −15% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Fakeeh Care right now?
Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Fakeeh Care

How large is the market capitalisation of Fakeeh Care (4017)?
The market capitalisation of Fakeeh Care is 7.0B SAR (≈ $1.9B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Fakeeh Care (4017)?
The price-to-sales ratio of Fakeeh Care is 2.25 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Fakeeh Care (4017)?
Earnings per share at Fakeeh Care are 1.01 SAR (price ÷ EPS = P/E 30.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Fakeeh Care (4017)?
The dividend yield of Fakeeh Care is 1.1% (payout 32.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Fakeeh Care (4017)?
The net margin of Fakeeh Care is 7.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Fakeeh Care (4017)?
The return on equity (ROE) of Fakeeh Care is 5.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Fakeeh Care (4017)?
On an EBIT basis the return on assets of Fakeeh Care is 7.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Fakeeh Care (4017)?
The operating margin of Fakeeh Care is 8.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Fakeeh Care (4017)?
Revenue at Fakeeh Care is growing −1.6% versus a year earlier (3y avg +15.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Fakeeh Care (4017)?
Earnings per share at Fakeeh Care are growing −30.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Fakeeh Care (4017) generate?
The free cash flow of Fakeeh Care is −48.5M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Fakeeh Care (4017) carry?
The net debt of Fakeeh Care is 737M SAR (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Fakeeh Care in the live analysis

One click puts Fakeeh Care on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.